Sorry, you need to enable JavaScript to visit this website.

Working To Reach Everyone, Everywhere


Our commitment to equitable access

Pfizer is firmly committed to equitable and affordable access to the Pfizer-BioNTech COVID-19 vaccine to help bring an end to the pandemic for everyone, everywhere.

As of December 11, 2022, more than 4,3 billion Pfizer-BioNTech COVID-19 vaccines were shipped to 181 countries in every region of the world.

Roll over the map for more information on Pfizer-BioNTech COVID-19 vaccine shipments.
Note: On mobile devices, click the country for vaccine shipment information.

Pfizer’s Pledge – 2 Billion Doses


In order to accelerate access for vulnerable populations, Pfizer pledged 2 billion doses – 1 billion in 2021 and 1 billion in 2022 – to low- and middle-income countries. We fulfilled our 2021 pledge in December 2021 and are working closely with governments and our partners to fulfill this pledge for 2022.

Pfizer-BioNTech doses reach countries through a number of supply pathways, including direct supply agreements with country governments, agreements with supranational organizations like the COVAX facility, government donation programs and humanitarian donation.

Pfizer and COVAX


Pfizer is a proud partner to the COVAX Facility, an international initiative led by the World Health Organization (WHO), Gavi, the Vaccine Alliance and Coalition for Epidemic Preparedness Innovations (CEPI) focused on equitable access to COVID-19 vaccines around the world. In 2021, Pfizer/BioNTech were a top contributor to COVAX, shipping more than 250 million doses – more than 25% of the total COVAX supply - to more than 100 countries and territories.

A substantial contribution to our partnership with COVAX is the agreement that Pfizer and BioNTech reached with the U.S. Government to provide one billion doses at the not-for-profit price, which the U.S. Government will, in turn, donate to Africa and the 92 COVAX Advanced Market Commitment (AMC) low- and lower-middle-income countries. Through this agreement 200 million doses were supplied through COVAX in 2021 and 800 million will be supplied in 2022.

Strengthening healthcare systems


Equitable access requires more than just the delivery of doses. Our commitment extends to the use of our resources to address urgent needs and make sure countries are ready to receive and distribute the vaccine to people in need.

Pfizer’s partnerships are wide-ranging: from our COVAX collaboration on supply chain capability analysis to freezer donation to support cold chain capacity through our UPS partnership.

Pfizer has also drawn on its long-term relationship with Zipline, using innovative solutions such as drone-assisted deliveries to ensure vaccines reach hard-to-reach areas.

The Pfizer Foundation has provided $30 million in grants to help meet the needs of front line healthcare workers during the pandemic - and we are continuing to work with NGOs, UN agencies and governments to explore the need for a targeted vaccine donation program for refugees and vulnerable populations.

  • How many of Pfizer’s doses are going to LMICs?

    We have committed to supplying 2 billion doses of our vaccine to low- and middle-income countries by the end of 2022 – at least 1 billion each year, and we will continue to explore new opportunities and pathways to expand our reach.

  • Where will the 2 billion doses Pfizer has pledged for LICs and MICs go?

    We have pledged 2 billion doses – 1 billion in 2021 and at least 1 billion in 2022 – to low- and middle-income countries through bilateral agreements, agreements with supranational organizations like COVAX, humanitarian relief programs and donation programs that allow wealthier nations to donate or share their doses with countries in need. In December 2021, we fulfilled our 2021 pledge and expect that we will surpass this total in 2022.

  • How have you priced your vaccine?

    During the pandemic, we are pricing our vaccine in a way that can help governments ensure that there is little to no out-of-pocket costs for their populations based on the principles of volume, advanced commitment, equity and affordability. Wealthier nations pay in the range of about the cost of a takeaway meal and offer it to their citizens for free. The upper-middle-income countries are offered doses at roughly half that price and the low- and lower-middle-income countries are offered doses at a not-for-profit price.

    Pfizer did not receive any public funding for the development of the Comirnaty® COVID-19 vaccine or for PAXLOVID™, Pfizer’s oral COVID-19 treatment. Any government funding received by our partner, BioNTech, was not a factor in setting Pfizer’s access strategies for the vaccine.

  • How will you ensure that the availability of boosters does not impact supply equity?

    The introduction of booster doses does not impact existing supply agreements with governments and international health organizations. Pfizer and BioNTech remain fully committed to working towards equitable and affordable access for COVID-19 vaccines for people around the world.

  • How are you addressing challenges with ultra cold chain handling requirements in low-income countries?

    While developing an mRNA-based vaccine, we immediately recognized that the ultra-cold chain requirements could present infrastructure challenges for some countries, which is why we began working with our distribution partners, simultaneous to development, to design a thermal shipping solution to mitigate the barriers that might exist for countries to effectively administer the vaccine.

    Since first submitting data for emergency use authorization in November 2020, Pfizer has been committed to testing the safety of new storage options at lower temperatures and for longer time periods. Following an initial recommendation to store our vaccine in ultra-cold chain conditions for a maximum of 30 days, followed by 5 days at refrigerator temperatures, we now have data to show that the vaccines can safely be stored at a higher temperature of -25°C to -15°C for two weeks, followed by one month at 2-8°C - reducing the impact for populations in harder to reach areas or with limited cold chain capacity.

  • How did you ensure the vaccine was going to be suitable for use in diverse populations around the world?

    We continue to prioritize diversity in clinical development and are designing our trials with that in mind, to ensure they are inclusive of populations that are more vulnerable or where burden of disease has been higher.

    Our landmark Phase 3 clinical trial enrolled 46,331 participants at 153 sites in Brazil, Argentina, Germany, Turkey, South Africa and the United States. Approximately 42% of global participants and 30% of U.S. participants in the Phase 3 study have racially and ethnically diverse backgrounds.

Emergency uses of Pfizer-BioNTech COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine, Bivalent have not been approved or licensed by FDA but have been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals aged 6 months and older as appropriate. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.